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ABSTRACT
The CDKN2A (p16) gene plays a key role in pancreatic cancer etiology. It is one 
of the most commonly somatically mutated genes in pancreatic cancer, rare germline 
mutations have been found to be associated with increased risk of developing familiar 
pancreatic cancer and CDKN2A promoter hyper-methylation has been suggested 
to play a critical role both in pancreatic cancer onset and prognosis. In addition 
several unrelated SNPs in the 9p21.3 region, that includes the CDNK2A, CDNK2B and 
the CDNK2B-AS1 genes, are associated with the development of cancer in various 
organs. However, association between the common genetic variability in this region 
and pancreatic cancer risk is not clearly understood. We sought to fill this gap in a 
case-control study genotyping 13 single nucleotide polymorphisms (SNPs) in 2,857 
pancreatic ductal adenocarcinoma (PDAC) patients and 6,111 controls in the context 
of the Pancreatic Disease Research (PANDoRA) consortium. We found that the A 
allele of the rs3217992 SNP was associated with an increased pancreatic cancer risk 
(ORhet=1.14, 95% CI 1.01-1.27, p=0.026, ORhom=1.30, 95% CI 1.12-1.51, p=0.00049). 
This pleiotropic variant is reported to be a mir-SNP that, by changing the binding site 
of one or more miRNAs, could influence the normal cell cycle progression and in turn 
increase PDAC risk. In conclusion, we observed a novel association in a pleiotropic 
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region that has been found to be of key relevance in the susceptibility to various types 
of cancer and diabetes suggesting that the CDKN2A/B locus could represent a genetic 
link between diabetes and pancreatic cancer risk.
INTRODUCTION
The majority of pancreatic cancer patients die within 
a year of diagnosis [1]. The poor prognosis is caused by 
various factors, including the lack of appropriate markers 
for early detection, the aggressiveness of the disease and 
the dearth of effective treatment possibilities available. 
One of the best strategies to reduce the mortality of the 
disease is to improve early diagnosis, and it is, therefore, 
important to identify individuals at high risk in the 
population and subject them to enhanced surveillance.
Only a few epidemiologic risk factors have been 
established for pancreatic cancer, including cigarette 
smoking, heavy alcohol intake, diabetes mellitus, obesity, 
chronic pancreatitis and family history of pancreatic cancer 
[2, 3]. Even less is known about the genetic contribution 
to the disease, since only a rather small number of 
susceptibility loci have been identified through genome-
wide association studies (GWAS) [4–9] and confirmed by 
follow-up studies [10]. Moreover it has been shown that 
a small proportion of pancreatic tumors arises as a result 
of high penetrance germline mutations in genes such as 
BRCA1, BRCA2, p16/CDKN2A, STK11/LKB, ATM, PALB2, 
and DNA mismatch repair genes, usually in the context of 
familial cancer syndromes [2, 3, 11–15]. However, the very 
low frequency of those mutations cannot explain the bulk of 
genetic susceptibility to pancreatic cancer.
There are compelling epidemiologic and molecular 
evidences pointing to a key role for the CDKN2A gene 
in pancreatic cancer etiology. CDKN2A is one of the 
most commonly somatically mutated genes in pancreatic 
cancer [16], rare germline mutations have been found to 
be associated with increased risk of developing familiar 
pancreatic cancer [15, 17], and also CDKN2A promoter 
hyper-methylation has been suggested to play a critical 
role both in pancreatic cancer onset and prognosis 
[18]. Additionally, the 9p21.3 region, that includes in 
addition to CDKN2A also CDKN2B and CDKN2B-AS1,is 
pleiotropic and several polymorphic variants in the region 
spanning the three genes are susceptibility markers for 
several cancer types [19–24]. In addition Li and colleagues 
performed an association study and meta-analysis across 
multiple cancers corroborating the pleiotropic role of the 
locus [25]. Several polymorphic variants in the region are 
also associated with type two diabetes mellitus (T2DM), 
which is a predisposing factor for pancreatic cancer, 
suggesting a possible role of the 9p21.3 region as a genetic 
link between the two diseases [26–28]. The pleiotropic 
role of the variants of this region is probably due to the 
central importance of the genes situated in it in cell cycle 
regulation. For example CDKN2A codes, by alternative 
splicing, for the two oncosuppressors p16INK4a and 
p14ARF [29, 30]. Despite all the hints pointing towards 
an association between common genetic variability in the 
CDKN2A/B gene region and pancreatic cancer risk no one 
has attempted to directly relate them so far. We sought to 
fill this gap in a case-control study genotyping 13 single 
nucleotide polymorphisms (SNPs) in the context of the 
PANcreatic Disease ReseArch (PANDoRA) consortium.
RESULTS
Data filtering and quality control
The characteristics of the population enrolled in 
the study are shown in Table 1. All analyzed SNPs were 
in HWE in controls (P>0.0038) with the exception of 
rs3731246 in the controls from Mannheim (Germany) 
and Southern Italy and rs2811710 in the controls from 
Mannheim. The populations not respecting the HWE were 
not included in the statistical analyses for the relevant 
SNPs. Starting from a population of 9,796 subjects, 
828 subjects with a call rate <75% were removed after 
genotyping, leaving 8,968 for further analysis. The 
average SNP call rate was 96% with a minimum of 79.95% 
(rs3731246) and a maximum of 99.19% (rs3218009). 
The analysis of the random duplicate samples showed a 
concordance rate of 99.68%. For the Japanese cases it was 
not possible to correctly genotype rs3731246 and therefore 
this SNP was not used in the risk analysis for the Japanese 
population. Supplementary Table S1 shows the call rate 
and the HWE equilibrium for each SNP.
SNP main effects
We analyzed separately Caucasian and Japanese 
individuals. For the individuals of Caucasian origin we 
observed that 6 SNPs showed a statistically significant 
association (p<0.05) with increased or decreased PDAC 
risk. The strongest association with an increased risk of 
PDAC was observed with the A allele of rs3217992 SNP 
(ORhet=1.14, 95% CI 1.01-1.27, p=0.026, ORhom=1.30, 
95% CI 1.12-1.51, p=0.00049, unadjusted p-trend =0.0002, 
adjusted p-trend= 0.32). Other, less significant associations 
were observed with rs3731249, rs2811708, rs3731211, 
and rs1063192. The frequencies and distributions of 
the genotypes (for the Caucasian group) and the OR for 
the association of each polymorphism with PDAC are 
described in Table 2. In the Japanese population the G allele 
of rs2811708 was associated with a decreased risk of PDAC 
(ORhet=0.58, 95% CI 0.36-0.95, p=0.029) and the A allele of 
rs1063192 was associated with a decreased risk of PDAC 
(ORhet=0.49, 95% CI 0.30-0.80, p=0.005, p-trend=0.03). 
The frequencies and distribution of the Japanese genotypes 
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and the OR for the association of each polymorphism with 
PDAC are described in Table 3.
Possible functional effects
We used several bioinformatic tools to predict 
possible functional relevance for the SNPs showing the 
most significant associations. Using Genevar, we observed 
that the C allele of rs3217992 was associated with increased 
expression of the interferon alpha 4 (IFNA4) gene (P=0.047). 
This association, however, was not below the threshold 
suggested by Genevar for significance (P<10-3). GTEx did 
not show any signifcant eQTL for any of the SNPs associated 
with pancreatic cancer risk. RegulomeDB showed a score of 
5, indicating the possible presence of a transcription factor 
binding motif or a DNase sensitivity peak for rs2811708, 
rs3217992 and rs1063192 and a score of 4 suggesting the 
presence of a transcription factor binding motif and a DNase 
sensitivity peak for rs3731211 and rs3731249. HaploReg did 
not suggest any relevant signals for the significant SNPs.
DISCUSSION
Several unrelated SNPs in the 9p21.3 region, that 
includes the CDNK2A, CDNK2B and the CDNK2B-AS1 
genes, are associated with the development of cancer in 
various organs [19-21, 23, 24, 31-33] and with T2D [26–
28]. In this study we have performed an in depth analysis 
of the region and found several promising associations 
between the common genetic variability and the disease 
onset. However, considering the correction for multiple 
testing only rs3217992 showed a statistically significant 
association with increased risk of developing PDAC.
This finding is interesting for two reasons. The first 
is that rs3217992 shows a plethora of associations with 
several human traits such as primary open-angle glaucoma 
[34], aggressive periodontitis, chronic periodontitis [35] 
and myocardial infarction [36]. These phenotypes are very 
different from each other, but all the studies, including 
the one presented here, have in common the fact that is 
always the A allele to be associated with the increased 
risk of the disease. This observation strongly suggests a 
pleiotropic role for rs3217992 and also highlights that the 
polymorphisms alters the function of the protein in a way 
that affects the related phenotypes. In recent years several 
pleiotropic SNPs have been identified to be associated 
with multiple human phenotypes or multiple cancer 
types. These pleiotropic stretches of DNA that are densely 
packed with risk alleles have been defined Nexus regions 
[37] and intensely studied in relation to cancer risk. PDAC 
Table 1: Characteristics of the studied population
Cases Controls Total
Median age (25%-75% 
percentiles)
65 (57-72) 57 (48-64)
Gender
 Males 1637 3371 5008
 Females 1182 2677 3859
 Unknown 38 63 101
Geographic origin
 Germany 1066 2282 3348
 Czech Republic 251 518 769
 Greece 80 175 255
 Italy Center 480 549 1029
 Italy North 361 595 956
 Italy South 114 500 614
 Lithuania 57 190 247
 Poland 87 335 422
 Netherlands 117 102 219
 UK 99 176 275
 Japan 145 689 834
Total 2857 6111 8968
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has at least another such region in the TERT-CLPTM1L 
locus as widely demonstrated by several authors [6, 9, 38].
The second reason is that in addition to the strong 
statistical association and the putative pleiotropic 
effect, rs3217992 SNP lies in a miRNA target region 
(miR-138-2-3p). In a very recent study Ghanbari and 
collaborators showed, using cardiac cell lines, that the 
rs3217992 SNP might have an effect on the miRNA-
mRNA interactions [39]. Specifically, the G allele 
increased the miRNA-dependent regulation of CDKN2B. 
Table 2: Association between the selected SNPs and PDAC risk in the Caucasian population
SNP Allelesa
(M/m)
Casesb
MM  Mm  mm
Controlsb
MM Mm mm
MM vs Mm
ORc 95% CIc
p MM vs mm
OR 95% CI
p p-trend 
adj
p-trend 
unadj
SNP 
Annotationd
rs3731257 C/T 1,362 1,082 211 2,567 2,007 354 0.99 0.89-1.10 0.83 1.07 0.88-1.31 0.476 0.419 0.30 5' flanking
rs11515 C/G 1,875 700 50 3,568 1,297 118 1.00 0.89-1.13 0.92 0.70 0.48-1.01 0.058 0.70 0.81 3' UTR
rs2518719 G/A 2,057 542 46 3,779 1,124 100 0.90 0.79-1.01 0.09 0.97 0.66-1.42 0.87 0.15 0.03 Intronic
rs3731249 C/T 2,496 159 5 4,140 341 9 0.75 0.60-0.92 0.007 0.64 0.19-2.07 0.45 0.14 0.01 Missense
rs3731246 C/G 1,814 450 37 1,842 515 30 0.85 0.73-0.99 0.04 1.10 0.65-1.85 0.72 0.39 0.32 Intronic
rs2811708 T/G 1,382 894 145 2,770 1,985 359 0.90 0.80-1.00 0.057 0.76 0.61-0.95 0.015 0.03 0.009 Intronic
rs3731239 C/T 1,066 1,193 313 2,237 2,365 673 1.06 0.96-1.19 0.25 0.99 0.84-1.18 0.92 047 0.82 Intronic
rs3731211 A/T 1,387 997 190 2,220 1,701 380 0.96 0.86-1.08 0.51 0.75 0.62-0.92 0.007 0.29 0.02 Intronic
rs2811710 T/C 1,087 1,207 333 1,413 1,636 504 1.00 088-1.12 0.97 0.88 0.74-1.05 0.17 0.26 0.08 Intronic
rs3218009 C/G 2,188 437 23 4,071 888 66 0.96 0.84-1.10 0.54 0.75 0.45-1.24 0.26 0.52 0.04 Intronic
rs3217992 G/A 821 1,332 504 1,807 2,543 868 1.14 1.01-1.27 0.026 1.30 1.12-1.51 0.0005 0.32 0.0002 3'UTR
rs1063192 G/A 1,011 1,219 341 1,756 2,291 722 0.89 0.80-0.99 0.047 0.82 0.70-0.97 0.019 0.55 0.009 3'UTR
rs3217986 C/A 2,243 392 17 4,511 810 28 0.97 0.84-1.12 0.71 1.48 0.78-2.82 0.23 0.14 0.89 3'UTR
a M = major allele (i.e. more common in controls); m = minor allele (less common in controls).
b Numbers may not add up to 100% due to genotyping failure, DNA depletion or covariate missing values.
C Odds ratio (95% confidence interval).
d as shown in Haploreg
All analyses were adjusted for age at diagnosis/age at recruitment, gender and country of origin.
Table 3: Association between the selected SNPs and PDAC risk in the Japanese population
SNP Allelesa
(M/m)
Casesb
MM Mm mm
Controlsb
MM Mm mm
MM vs Mm
OR 95% CI
p MM vs mm
OR 95% CI
p p-trend 
adj
p-trend 
unadj
rs3731257 C/T 24 68 49 128 336 204 1.10 0.66-1.83 0.71 1.30 0.76-2.23 0.33 0.41 0.32
rs11515 C/G 131 7 0 643 17 0 1.97 0.80-4.85 0.14 - 1.00 0.12
rs2518719 G/A 145 0 0 667 0 0 - - - -
rs3731249 C/T 136 0 0 683 0 0 - - - -
rs2811708 T/G 101 23 5 452 176 18 0.58 0.36-0.95 0.029 1.23 0.45-3.41 0.68 0.59 0.15
rs3731239 C/T 109 27 2 507 164 14 0.76 0.48-1.21 0.25 0.66 0.15-2.96 0.59 0.24 0.22
rs3731211 A/T 97 38 9 429 218 20 0.77 0.51-1.16 0.21 2.01 0.89-4.55 0.09 0.85 0.97
rs2811710 T/C 82 52 9 376 272 36 0.87 0.59-1.27 0.48 1.15 0.53-2.47 0.73 0.41 0.81
rs3218009 C/G 143 0 0 687 0 0 - -
rs3217992 G/A 28 44 50 128 289 218 0.70 0.41-1.17 0.17 1.05 0.63-1.75 0.85 0.44 0.59
rs1063192 G/A 99 22 9 432 198 32 0.49 0.30-0.80 0.005 1.23 0.57-2.66 0.60 0.03 0.11
rs3217986 C/A 130 14 0 622 66 0 1.00 0.55-1.85 0.98 0.06 0.96
a M = major allele (i.e. more common in controls); m = minor allele (less common in controls).
b Numbers may not add up to 100% due to genotyping failure, DNA depletion or covariate missing values.
C Odds ratio (95% confidence interval).
All analyses were adjusted for age at diagnosis/age at recruitment, gender and country of origin.
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Given the role of CDKN2B in the cell cycle this result 
seems counterintuitive since the A allele is associated with 
increased risk in our study and in others as mentioned 
before. The 9p21.3 locus has, however, a very complex 
regulation, and it is possible that the binding between 
the G allele and miR-138-2-3p might be specific for the 
cardiac tissue. Moreover the 9p21.3 locus hosts several 
genes that are key cell cycle regulators and therefore 
the fact that rs3217992 changes the binding site of one 
or more miRNAs could influence the normal cell cycle 
progression and in turn increase PDAC risk. There are 
growing evidences that mir-SNPs could be involved 
in various pathologies including cancer and diabetes 
given their ability to affect gene regulation. However, 
the functional significance of this SNP needs thorough 
scrutiny in the pancreatic tissue to address its possible role 
in PDAC susceptibility.
Another finding of potential significance is the 
association between the A allele of rs1063192 with 
decreased PDAC risk. This SNP also lies in the CDKN2B 
3'UTR, is a putative mir-SNP and shows a weak linkage 
disequilibrium (LD) with rs3217992 (r2=0.474 in CEU 
and r2=0.170 CHBJPT, 1000 Genomes Project). Li 
and colleagues found this SNP to be associated with 
esophageal squamous cell carcinoma [25], while in a 
recent report [40] the A allele of rs1063192 was found 
to be associated with a decreased risk of developing 
gestational diabetes mellitus (GDM) suggesting a direct 
genetic link between diabetes and pancreatic cancer 
though the genetic variants analyzed in both studies.
The strongest association we observed in the 
Japanese population was between the A allele of 
rs1063192 and a decreased PDAC risk. This finding gives 
rise to two considerations: the first is that even though the 
association does not reach the threshold of significance 
considering Bonferroni's correction, it is unlikely to be 
a false finding giving the fact that it was found in two 
different populations. The second is that since in the 
Caucasian and in the Japanese the leading SNP is not 
the same it is possible that the real causal variant is yet 
untyped and mildly in LD with rs1063192 and rs3217992.
We also observed an association close to statistical 
significance (taking into account multiple testing) between 
the missense SNP rs3731249 and PDAC susceptibility. 
This variation is predicted by PolyPhen to be possibly 
damaging with a score of 0.487 and has been widely 
investigated in childhood acute lymphocytic leukemia [23, 
24, 41], once again highlighting the pleiotropic nature of 
this genomic region. Through dbGaP we could perform a 
GWAS look-up for the results of our candidate SNPs. We 
found results only for Caucasians (PanScan2, [6]) and only 
for three of the significant SNPs rs2811708, rs3217992 
and rs1063192. All the SNPs showed ORs that were in 
the same direction with our results but none showed a 
statistically significant association, the best was p=0.08 for 
rs1063192. In 2 out of 3 populations (PANDoRA Japanese 
and PanScan) tested the best association was observed 
for rs1063192 and in the last population (PANDoRA 
Caucasians) for rs3217992. The two SNPs are in weak LD. 
This suggests the hypothesis that another variant (possibly 
a low frequency/rare one) may be associated with both, 
that was not typed in either population and that has an LD 
pattern with rs1063192 and rs3217992 that varies in the 
different populations. The difference in the results between 
PANDoRA and PanScan may be explained by the fact that 
in PANDoRA the strongest statistical association was 
observed for the rare homozygous carriers compared with 
the common allele carriers suggesting a recessive model 
of inheritance, while in the PanScan data only the allelic 
model is shown. Additionally, the results from PanScan 
arise partly from a prospective cohort while ours are from a 
case-control study. Although the biological explanation of 
this phenomenon is difficult to understand, discrepancies 
between the two study designs have been observed several 
times in different neoplastic diseases [4, 21, 42, 43].
One of the major strengths of this study is its size, 
since with a total of 8,968 subjects this is one the largest 
genetic analysis of pancreatic cancer risk published to-
date. Additionally, our selection of SNPs provides an 
extensive coverage of genetic variability in the regions of 
interest. In addition we could analyze simultaneously two 
ethnic groups, which helps to generalize the findings. A 
possible limitation of the study is that patients and controls 
in PANDoRA were recruited in various centers across 
Europe and therefore there might be some population-
based differences. Moreover we did not include rare 
variants and therefore we cannot exclude to have missed 
associations due to alleles with a MAF<0.05.
In conclusion we observed several novel 
associations in a pleiotropic region that has been found 
to be of key relevance in the susceptibility to various 
types of cancer and diabetes, confirming a key role for 
CDKN2A/B in pancreatic cancer and suggesting a possible 
involvement of the common genetic variability at this 
locus in PDAC risk.
MATERIALS AND METHODS
Study population
In this study 2,857 pancreatic ductal 
adenocarcinoma (PDAC) patients and 6,111 controls 
were collected in nine countries (Germany, Czech 
Republic, Greece, Italy, Lithuania, Poland, Netherlands, 
UK and Japan) belonging to the PANDoRA consortium 
that has been described in detail elsewhere [44]. Briefly, 
cases were retrospectively collected and are defined by a 
confirmed diagnosis of PDAC. Controls were recruited in 
the same hospitals, or at least geographical region from 
where the cases were recruited. British and Dutch controls 
(N=176 and 102, respectively) were selected from healthy 
volunteers recruited from the general population in the 
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European Prospective Investigation on Cancer (EPIC), 
an ongoing prospective cohort being carried out in ten 
European countries [45]. The German controls used were 
partly blood donors from the blood transfusion center in 
Mannheim and partly healthy volunteers selected among 
EPIC subjects collected in Heidelberg. Patients provided 
written informed consent and the study was approved by 
Ethical Review Board of the University of Heidelberg 
(Medizinische Facultaet Heidelberg) the study was 
performed in accordance with Declaration of Helsinki.
SNP selection
To survey the common genetic variability in the 
CDKN2A/B locus we selected tagging SNPs using the 
Tagger tool of the Haploview software using the Caucasian 
population in the HapMap web site (International HapMap 
Project, version 28; http://www.hapmap.org) as reference 
(http://www.broad.mit.edu/mpg/haploview/; http://www.
broad.mit.edu/mpg/tagger/). We considered a region 
centered on the CDKN2A gene region and we added 5k 
bp at 5' and 5k at 3' of the gene resulting in a window of 
around 40k base pair. We used a pairwise tagging method 
with a minimum r2 of 0.8 and a minor frequency allele 
of 0.05 to select tagging SNPs inside the region. The 
first tagging SNP at the 5' end, rs3731257, is situated at 
21956221 (Hg18) while the last tagging SNP at the 3' end, 
rs3217986, is situated at 21995330 (Hg18). In addition we 
added two functional SNPs (rs1063192 and rs3217992) 
that are putative miR-SNPs, i.e. predicted to alter the 
binding of one or more microRNAs to their target. The 
final selection resulted in 13 SNPs in the 9p21.3 region. 
We checked if the tagging selection used was valid also 
for the Asian ethnicities and we obtained that the tagging 
set for Chinese and Japanese is a subset of the one used 
for Caucasians.
Sample preparation and genotyping
For each sample DNA was extracted from whole 
blood or from paraffin-embedded pancreatic tissues of 
patients and controls using the AllPrep Isolation Kit 
(Qiagen, Hilden, Germany) or the Qiagen-mini kit (Qiagen, 
Hilden, Germany), according to the manufacturer’s 
protocol. Genotyping was performed using TaqMan (ABI, 
Applied Biosystems, Foster City, CA, USA) and KASPar 
(KBioscence, Hoddesdon, UK) technologies. The order 
of DNA samples was randomized on plates in order to 
ensure that similar numbers of cases and controls were 
analyzed in each batch. Detection was performed using an 
ABI PRISM 7900 HT or Viia7 sequence detection system 
with SDS 2.2 or Viia7 software (Applied Biosystems, 
Foster City, CA, USA). Genotyping for British and Dutch 
controls was performed in the context of a genome-wide 
association study using the Human 660W-Quad BeadChip 
array according to manufacturer’s instructions (Illumina, 
San Diego, CA, USA). For quality control, duplicates 
of 10% of the samples were interspersed throughout the 
plates. In addition, we discarded all the samples that had 
a call rate < 75%.
Statistical analysis
The observed genotype frequencies of all SNPs 
in the control subjects were tested for deviation from 
Hardy–Weinberg equilibrium (HWE) using Pearson’s 
chi-square test. The association between the genotypes of 
all polymorphisms and PDAC risk was estimated using 
an unconditional logistic regression computing odds 
ratios (OR), 95% confidence intervals (95% CIs) and p 
values. The more common allele among the controls was 
assigned as the reference category and the co-dominant 
model inheritance model was assessed. All analyses were 
adjusted for age, gender and geographic origin (among the 
Europeans countries). European and Japanese individuals 
were kept separate in the analyses. All analyses were 
adjusted for multiple testing using the Bonferroni 
correction whereby a significance threshold of 0.0038 
(0.05/13) was set.
Bioinformatic analysis
To assess the possible functional relevance for the 
SNPs showing the most significant associations with 
risk of developing PDAC several bioinformatic tools 
were used. RegulomeDB (http://regulome.stanford.
edu/)[46] and HaploReg v2B [47] were used to identify 
the regulatory potential of the region nearby each SNP. 
Genevar (http://www.sanger.ac.uk/resources/software/
genevar/) [48] and GTEx (http://www.gtexportal.org/
home/)[49] were used to identify potential associations 
between the SNP and expression levels of nearby genes 
(eQTL).
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